top of page
Search

INCREASED RISK OF MYOCARDITIS OR PERICARDITIS IN PERSONS AGED 12 -50 YEARS AFTER COVID VACCINATION

Introduction :


In the provisional, conditional, authorisation to commercialise the experimental Pfizer vaccine dd.21.12.2020 ( and for that matter also in the provisional conditional authorisation of later date to Moderna ), Myocarditis and Pericarditis are explicitly listed as HIGH RISK ADVERSE EVENTS ( high risk side effects ). The EU, all governments and experts wiped their coffers on that and decided to proceed with mass vaccination anyway.


Apparently ( cf the text of the study below ), the EMA advised on 19 July 2021 that both myocarditis and pericarditis would be included in the list of side effects of corona vaccines. This advice was due to several pharmacological vigilance reports that had shown that there was an increased risk of myocarditis after vaccination and these conditions all followed a similar pattern. Several reports showed that adverse events typically occurred within the week after vaccination, but especially after the second dose, and mainly in young men. As for pericarditis, the course was uncertain.





10 French scientists initiated a study on these conditions. Their study was published on 25.06.2022 in the leading scientific magazine NATURE. https://www.nature.com/articles/s41467-022-31401-5





The scientists focused their research on the entire French population between 12 and 50 years of age during the period from May 12, 2021 to October 31, 2021 ( either the period when mass vaccination opened for individuals under 50 years of age ). The study is based on data from the National Health Data System that records data from 99% of the population ( 67 million people ) and on data from all French hospitals, specifically the discharges ( of sick people ) from hospitals database ( PMSI ) linked to the national vaccination database for Covid19 ( VaC-SI ) and the database that records test results ( Si-DEP ) and more specifically on all patients admitted to a French hospital with the diagnosis of myocarditis or pericarditis during the set period. Each person with conditions was examined separately.


Exposure ( to mRNA ) was defined as vaccination with an mRNA vaccine 1 to 7 days or 8 to 21 days before the index date where the first and second doses were examined separately. Unvaccinated persons and all those vaccinated more than 21 days before the index date were recorded as " not exposed " ( to mRNA ). Persons with a pre-existing history of myocarditis or pericarditis for 5 years before the index date and who were hospitalised during the set period of study were registered with an ICD-10 code and excluded from the study.


The scientists argue that they encountered several limitations in their study. The NHDS database contains very few, if any, clinical and laboratory studies on the cases in question ( i.e. those admitted to hospitals with myocarditis or pericarditis ) These individuals could only be identified based on the diagnosis codes used by hospitals. Consequently, the study team was unable to detect asymptomatic cases or mild forms of myocarditis or pericarditis not requiring hospitalisation.


CONCLUSION (in original text)


The risk of myocarditis was substantially increased within the first week post vaccination in both males and females.


An increased risk of pericarditis was also found in the first week after the second dose of either of the mRNA vaccines among both males and females (Fig. 2 and Table S3).


For both vaccines, the risk of myocarditis was increased in the seven days post vaccination (Table 2; in the rest of the text, we will refer to multivariable odds ratios). For the BNT162b2 vaccine, odds ratios were 1.8 (95% confidence interval [CI]: 1.3–2.5) for the first dose and 8.1 (95% CI, 6.7–9.9) for the second. The association was stronger for the mRNA-1273 vaccine with odds-ratios of 3.0 (95% CI, 1.4–6.2) for the first dose and 30 (95% CI, 21–43) for the second. The risk of pericarditis was increased in the seven days following the second dose of both vaccines, with odds ratios of 2.9 (95% CI, 2.3–3.8) for the BNT162b2 vaccine and 5.5 (95% CI, 3.3–9.0) for the mRNA-1273 vaccine. Vaccination in the previous 8 to 21 days, with either the BNT162b2 or mRNA-1273 vaccine was not associated with a risk of myocarditis or pericarditis. Independently of vaccination status, a history of myocarditis was strongly associated with a risk of contracting myocarditis during the study period, with an odds-ratios of 160 (95% CI, 83–330). The same was true for pericarditis, with an odds ratio of 250 (95% CI, 120–540). No interaction was found between history of myocarditis or pericarditis and vaccine exposure.


Among exposed cases, the delay between administration of the vaccine and hospitalization (Fig. S2) was shorter after the second dose than after the first dose, both for myocarditis (median of 4 days versus 10 days after the BNT162b2 vaccine and of 3.5 days versus 9 days after the mRNA-1273 vaccine) and for pericarditis (median of 6 days versus 10 days after the BNT162b2 vaccine and of 3 days versus 11 days after the mRNA-1273 vaccine).


There are several factors that support the hypothesis of a causal relationship between exposure to mRNA vaccines and the risk of myocarditis and pericarditis. First, the associations remained strong, even after adjusting for a history of these conditions or recent SARS-CoV-2 infection, and in a period during which most common respiratory viruses were not widely circulating26,27. Second, the time that elapsed between exposure to the vaccine and hospitalization was very short for both conditions, particularly after the second dose. Third, in most cases, the associations did not persist after seven days following exposure. Fourth, the stronger risk associated with the second dose and the mRNA-1273 vaccine, which contains a larger amount of mRNA, suggest a dose response relationship.




Although these serious side effects (which are associated with a sharp increase in cardiovascular diseases and SADs) have been known since at least December 2020 and if not at least since July 2021, Minister Crevits wants to introduce a new vaccination round from September 2022 onwards (for a fourth vaccination or the third for those who have not yet taken it) and Minister Frank VDB is still forcing the health care sector to vaccinate via a legal obligation....


Too crazy for words especially when one considers that the list of side effects is not limited to risk of myocarditis or pericarditis in 12 to 50 year olds, but includes a long list of other serious conditions and side effects ( see Pfizer's working paper in an earlier post & the Vaers, Eudravigilance and VigiAcess databases )



Fig. 1: Association between myocarditis and exposure to mRNA vaccines within 7 days, according to sex and age group.



0 views0 comments
bottom of page